BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36982928)

  • 1.
    Vaicekauskaitė I; Dabkevičienė D; Šimienė J; Žilovič D; Čiurlienė R; Jarmalaitė S; Sabaliauskaitė R
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
    Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
    BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
    Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
    J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer.
    Vaicekauskaitė I; Sabaliauskaitė R; Lazutka JR; Jarmalaitė S
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
    Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
    J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
    Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW
    Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
    Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
    Elife; 2017 Oct; 6():. PubMed ID: 28967863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circular RNA circ-BNC2 (hsa_circ_0008732) inhibits the progression of ovarian cancer through microRNA-223-3p/ FBXW7 axis.
    Liu T; Yuan L; Zou X
    J Ovarian Res; 2022 Aug; 15(1):95. PubMed ID: 35965327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ.
    Chang L; Azzolin L; Di Biagio D; Zanconato F; Battilana G; Lucon Xiccato R; Aragona M; Giulitti S; Panciera T; Gandin A; Sigismondo G; Krijgsveld J; Fassan M; Brusatin G; Cordenonsi M; Piccolo S
    Nature; 2018 Nov; 563(7730):265-269. PubMed ID: 30401838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
    Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.
    Jones S; Stransky N; McCord CL; Cerami E; Lagowski J; Kelly D; Angiuoli SV; Sausen M; Kann L; Shukla M; Makar R; Wood LD; Diaz LA; Lengauer C; Velculescu VE
    Nat Commun; 2014 Sep; 5():5006. PubMed ID: 25233892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SKOV3 cells containing a truncated ARID1a protein have a restricted genome-wide response to glucocorticoids.
    Stubbs FE; Birnie MT; Biddie SC; Lightman SL; Conway-Campbell BL
    Mol Cell Endocrinol; 2018 Feb; 461():226-235. PubMed ID: 28942102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of ARID1A mutation on molecular characteristics in colorectal cancer.
    Tokunaga R; Xiu J; Goldberg RM; Philip PA; Seeber A; Battaglin F; Arai H; Lo JH; Naseem M; Puccini A; Berger MD; Soni S; Zhang W; Chen S; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
    Eur J Cancer; 2020 Nov; 140():119-129. PubMed ID: 33080474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
    Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA‑223‑induced inhibition of the
    Liu Z; Ma T; Duan J; Liu X; Liu L
    Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33355365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SWI/SNF protein and claudin-4 expression in anaplastic carcinomas arising in mucinous tumours of the ovary and retroperitoneum.
    Chaudet K; Kem M; Lerwill M; Young RH; Mino-Kenudson M; Agaimy A; McCluggage WG; Oliva E
    Histopathology; 2020 Aug; 77(2):231-239. PubMed ID: 32268438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
    Guan B; Wang TL; Shih IeM
    Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jagged1 expression regulated by Notch3 and Wnt/β-catenin signaling pathways in ovarian cancer.
    Chen X; Stoeck A; Lee SJ; Shih IeM; Wang MM; Wang TL
    Oncotarget; 2010 Jul; 1(3):210-8. PubMed ID: 20953350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.